Coya Therapeutics shares are trading higher after the company announced the publication of a peer-reviewed manuscript titled, "A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis," in the medical journal Frontiers in Neurology.
Portfolio Pulse from Benzinga Newsdesk
Coya Therapeutics shares are trading higher following the publication of a peer-reviewed manuscript in Frontiers in Neurology. The study evaluates the safety, tolerability, and biological marker responses of a combination therapy for Amyotrophic Lateral Sclerosis (ALS).
June 11, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coya Therapeutics shares are trading higher after the publication of a Phase 1 study on ALS therapy in Frontiers in Neurology. The study shows promising results in safety, tolerability, and biological marker responses.
The publication of a peer-reviewed study in a reputable journal like Frontiers in Neurology is a significant milestone for Coya Therapeutics. Positive results in safety, tolerability, and biological marker responses can boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100